Melanomas are known to harbour activating mutations in RAS and/or BRAF suggesting that the downstream effector Extracellular signal-regulated kinase (ERK) may be playing a major role in the oncogenic behavior of these tumors10. This evidence concerns the gene BRAF and melanoma.